Every year, millions of Americans face a brutal choice: pay for their medicine or pay for rent, groceries, or electricity. It’s not a hypothetical dilemma - it’s daily reality for people with diabetes, cancer, or rare diseases. The same pill that costs $30 in Canada or €25 in Germany can cost over $500 in the U.S. Why? The answer isn’t one thing. It’s a system built over decades that rewards profit over people.
The System Is Designed This Way
The U.S. doesn’t have high drug prices because of bad luck or corporate greed alone. It’s because the rules were written to allow it. In 2003, Congress passed the Medicare Modernization Act. One clause stood out: Medicare was banned from negotiating drug prices with manufacturers. That’s not how it works anywhere else in the developed world. Countries like the UK, Germany, and Canada negotiate directly. They say, “We’ll buy this drug, but not at your list price.” The U.S. said nothing. That single decision gave drug companies a blank check. Fast forward to 2025, and the results are clear. Americans pay over three times more for brand-name drugs than people in other OECD countries. The same medication - Galzin for Wilson’s disease - costs $88,800 a year here. In the UK, it’s $1,400. That’s not a pricing error. That’s a policy choice.Who’s Really in Charge? Meet the Middlemen
You might think drug prices are set by manufacturers alone. But there’s a hidden layer: Pharmacy Benefit Managers, or PBMs. These are the middlemen between drug makers, insurers, and pharmacies. Originally, they were supposed to cut costs by negotiating discounts. Today, they’re big corporations that own pharmacies, insurance plans, and even drug manufacturers. Their profit? It comes from rebates - and the higher the list price, the bigger the rebate. Here’s how it works: A drug company sets a list price of $1,000. The PBM negotiates a $300 rebate. The final price to the insurer is $700. But the list price stays at $1,000. That’s the number you see on your pharmacy receipt. The patient pays based on that inflated price - even if their insurance only covers part of it. So PBMs have a financial incentive to keep prices high. It’s a perverse system where the people meant to lower costs actually profit from them.Specialty Drugs Are Breaking the Bank
Not all drugs are created equal. The biggest price spikes come from specialty drugs - treatments for cancer, rare diseases, obesity, and diabetes. These aren’t generic pills. They’re complex biologics, often made with cutting-edge science. But that doesn’t justify what’s happening. Take Ozempic and Wegovy. These drugs for diabetes and weight loss cost over $1,000 a month in the U.S. In 2025, the White House announced deals with manufacturers to cut those prices to $350. That’s progress. But here’s the catch: those deals only apply to Medicare. Millions of people with private insurance still pay full price. And even $350 a month is $4,200 a year - more than most people spend on rent. IQVIA reports that novel obesity and diabetes drugs drove an 11.4% increase in U.S. drug spending in 2024. That’s not just inflation. That’s a business model built on locking patients into lifelong, high-cost therapies.
The Inflation Reduction Act - A Start, But Not a Solution
In 2022, Congress passed the Inflation Reduction Act. For the first time, Medicare could negotiate prices for a small number of drugs. In 2026, that list includes ten drugs - all high-cost, high-demand medications. The projected savings? $1.5 billion in out-of-pocket costs for seniors. That sounds good. But look closer. There are 10,000+ prescription drugs on the market. Ten is less than 0.1%. And even that limited power was weakened in 2025 by a budget reconciliation bill that reduced funding for the negotiation program. Meanwhile, drug companies are still allowed to raise prices faster than inflation - unless they’re on the negotiation list. For the rest? No limits. The law also created a $2,000 annual cap on out-of-pocket drug costs for Medicare beneficiaries. That’s huge. For someone taking three expensive medications, that could mean saving $5,000 a year. But it only helps seniors on Medicare. It doesn’t touch the 150 million Americans with private insurance.Why Other Countries Don’t Have This Problem
Germany uses reference pricing. If a new drug costs more than similar ones already on the market, the government says, “We won’t pay more than the average.” France negotiates directly with manufacturers before a drug even hits shelves. Canada uses bulk purchasing and price caps. None of them let companies set prices at will. The U.S. is the only OECD country without any form of direct price control. And it’s not because we’re smarter or more innovative. It’s because we have a powerful pharmaceutical lobby that spends over $300 million a year on lobbying and campaign donations. The system works perfectly - for them.